Ignite Creation Date:
2025-12-24 @ 10:42 PM
Ignite Modification Date:
2026-02-08 @ 3:33 PM
Study NCT ID:
NCT04679935
Status:
COMPLETED
Last Update Posted:
2025-09-26
First Post:
2020-12-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Age-related Macular Degeneration | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | neovascular age-related macular degeneration | View |
| None | anti-VEGF | View |
| None | choroidal neovascularization | View |
| None | brolucizumab | View |
| None | loading vs. non-loading | View |
| None | Macular degeneration | View |
| None | age-related macular degeneration (ARMD) | View |
| None | vision loss | View |
| None | macula damage | View |
| None | retina damage | View |
| None | dry macular degeneration | View |
| None | wet macular degeneration | View |
| None | Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration | View |
| None | Retinal Degeneration | View |
| None | Retinal Diseases | View |
| None | Eye Diseases | View |